title: Safety of intracameral injection of moxifloxacin using total replacement technique (bag and chamber flushing).
abstract: OBJECTIVE
  To assess the safety of intracameral injection of moxifloxacin (MFLX) using the total replacement technique [bag and chamber (BC) flushing].
  
  
  METHODS
  The anterior chamber including the area behind the intraocular lens was irrigated and replaced using BC flushing. In Group A, 36 patients received balanced salt solution irrigation in the right eye and intracameral MFLX (150 μg/mL: 33-fold dilution of 0.5% eye drops) in the left eye. In Group B, 33 patients received intracameral MFLX in the right (500 μg/mL: 10-fold dilution) and left eyes (150 μg/mL: 33-fold dilution). Visual acuity, intraocular pressure, corneal endothelial cell density, corneal thickness, and foveal thickness were recorded before and up to 3 months after surgery.
  
  
  RESULTS
  In either group, there were no statistically significant differences between the right and left eyes with respect to visual acuity, intraocular pressure, corneal endothelial cell count, and foveal thickness before and at 3 months after surgery. There was no difference in corneal thickness before and at 3 months after surgery. In patients who received 500 μg/mL MFLX during surgery, central corneal thickness at 1 week after surgery was significantly reduced.
  
  
  CONCLUSIONS
  In the present study, there was no adverse effect associated with intracameral injection of 150-500 μg/mL MFLX. Moreover, our results supported the safety of BC flushing. Thus, BC flushing, which can irrigate the inside of the capsular bag and attain stable antibiotic concentrations, appears to be a favorable technique for intracameral injection of MFLX.
authors.affiliation: 1 Department of Ophthalmology, Nojima Hospital , Kurayoshi-city, Japan .
authors.forename: Kazuki
authors.initials: K
authors.lastname: Matsuura
authors.forename: Chikako
authors.initials: C
authors.lastname: Suto
authors.forename: Yoshitsugu
authors.initials: Y
authors.lastname: Inoue
authors.forename: Shin-ichi
authors.initials: S
authors.lastname: Sasaki
authors.forename: Shoko
authors.initials: S
authors.lastname: Odawara
authors.forename: Takahiro
authors.initials: T
authors.lastname: Gotou
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000867:Anterior Chamber / Q000378:metabolism*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003315:Cornea / Q000187:drug effects / Q000378:metabolism; D004728:Endothelium, Corneal / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D056965:Injections, Intraocular; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D007507:Therapeutic Irrigation / Q000379:methods; D013997:Time Factors; D014792:Visual Acuity / Q000187:drug effects*
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D009883:Ophthalmic Solutions; D000077266:Moxifloxacin